NasdaqGS - Delayed Quote • USD
ACADIA Pharmaceuticals Inc. (ACAD)
At close: May 31 at 4:00 PM EDT
After hours: May 31 at 4:57 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 18 | 19 | 19 |
| Avg. Estimate | 0.19 | 0.18 | 0.58 | 1.13 |
| Low Estimate | 0.09 | 0.07 | 0.29 | 0.52 |
| High Estimate | 0.34 | 0.34 | 0.85 | 2.13 |
| Year Ago EPS | 0.01 | -0.4 | -0.37 | 0.58 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 18 | 18 | 19 | 19 |
| Avg. Estimate | 235.58M | 249.8M | 953.86M | 1.07B |
| Low Estimate | 225M | 235M | 919.49M | 1B |
| High Estimate | 242.67M | 256M | 981.14M | 1.2B |
| Year Ago Sales | 157.81M | 211.7M | 726.44M | 953.86M |
| Sales Growth (year/est) | 49.30% | 18.00% | 31.30% | 12.60% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.08 | -0.43 | 0.3 | 0.05 |
| EPS Actual | 0.01 | -0.4 | 0.28 | 0.1 |
| Difference | 0.09 | 0.03 | -0.02 | 0.05 |
| Surprise % | 112.50% | 7.00% | -6.70% | 100.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.19 | 0.18 | 0.58 | 1.13 |
| 7 Days Ago | 0.19 | 0.18 | 0.57 | 1.11 |
| 30 Days Ago | 0.19 | 0.22 | 0.64 | 1.25 |
| 60 Days Ago | 0.2 | 0.23 | 0.67 | 1.28 |
| 90 Days Ago | 0.23 | 0.24 | 0.78 | 1.46 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 8 | 2 | 4 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ACAD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 1,800.00% | -- | -- | 7.70% |
| Next Qtr. | 145.00% | -- | -- | 10.10% |
| Current Year | 256.80% | -- | -- | 4.60% |
| Next Year | 94.80% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -357.00% | -- | -- | 11.29% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | B of A Securities: Neutral to Neutral | 5/10/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/9/2024 |
| Maintains | Citigroup: Buy to Buy | 5/9/2024 |
| Maintains | Stifel: Hold to Hold | 5/9/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 5/9/2024 |
| Maintains | Mizuho: Neutral to Neutral | 5/9/2024 |
Related Tickers
FOLD Amicus Therapeutics, Inc.
9.80
-0.81%
AXSM Axsome Therapeutics, Inc.
73.43
-1.05%
INCY Incyte Corporation
57.79
+0.86%
SAGE Sage Therapeutics, Inc.
11.11
-3.39%
BMRN BioMarin Pharmaceutical Inc.
75.07
+0.79%
ARWR Arrowhead Pharmaceuticals, Inc.
22.95
+0.75%
EXEL Exelixis, Inc.
21.69
+4.38%
ALNY Alnylam Pharmaceuticals, Inc.
148.43
-1.07%
SRPT Sarepta Therapeutics, Inc.
129.86
+4.35%
APLS Apellis Pharmaceuticals, Inc.
39.25
-3.68%